The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice-Reference-Cited by-同舟云学术

The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice

Published:2020-12-17 Issue:6 Volume:93 Page:3484-3495
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J Med Virol

Author:

Yamaya Mutsuo¹²^ORCID,Shimotai Yoshitaka³,Ohkawara Ayako⁴,Bazarragchaa Enkhbold⁴,Okamatsu Masatoshi⁴,Sakoda Yoshihiro⁴⁵,Kida Hiroshi⁵⁶,Nishimura Hidekazu¹

Affiliation:

1. Virus Research Center, Clinical Research Division Sendai Medical Center Sendai Japan

2. Department of Respiratory Medicine Tohoku University Graduate School of Medicine Sendai Japan

3. Department of Infectious Diseases, Faculty of Medicine Yamagata University Yamagata Japan

4. Laboratory of Microbiology, Faculty of Veterinary Medicine Hokkaido University Sapporo Japan

5. Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI‐CoRE) Hokkaido University Sapporo Japan

6. Research Center for Zoonosis Control Hokkaido University Sapporo Japan

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.26700

Reference48 articles.

1. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza

2. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life

3. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

4. Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in Mexico

5. Morbidity and Mortality Associated With Nosocomial Transmission of Oseltamivir- Resistant Influenza A(H1N1) Virus

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nafamostat mesylate decreases skin flap necrosis in a mouse model of type 2 diabetes by protecting the endothelial glycocalyx;Biochemical and Biophysical Research Communications;2024-05

2. Organotypic lung tissue culture as a preclinical model to study host- influenza A viral infection: A case for repurposing of nafamostat mesylate;Tissue and Cell;2024-04

3. Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia;International Journal of Infectious Diseases;2023-03

4. Nafamostat mesylate as a broad-spectrum candidate for the treatment of flavivirus infections by targeting envelope proteins;Antiviral Research;2022-06

5. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model;mBio;2022-02-22